MedPath

Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-

Randomized Controlled Trials of the Effects of Decadron on Swallowing, Airway, and Arthrodesis

Phase 1
Conditions
Swallowing
Interventions
Drug: Saline
Drug: Decadron
First Posted Date
2010-02-10
Last Posted Date
2010-02-10
Lead Sponsor
Albany Medical College
Target Recruit Count
200
Registration Number
NCT01065961
Locations
🇺🇸

Albany Medical Center, Albany, New York, United States

Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma

Phase 1
Completed
Conditions
Bronchiolitis
Interventions
Drug: Dexamethasone
Drug: Placebo
First Posted Date
2010-02-09
Last Posted Date
2016-08-10
Lead Sponsor
Hamad Medical Corporation
Target Recruit Count
200
Registration Number
NCT01065272
Locations
🇶🇦

Hamad Medical Corporation, Pediatric Emergency Center,Alsaad., Doha, Qatar

The Adrenal Contribution to Androgen Production in Girls During Puberty

Phase 3
Completed
Conditions
Development
Interventions
Drug: Adrenocorticotropin
Drug: Dexamethasone
First Posted Date
2010-02-04
Last Posted Date
2019-08-26
Lead Sponsor
University of California, San Diego
Target Recruit Count
50
Registration Number
NCT01062568
Locations
🇺🇸

University of california, san diego, La Jolla, California, United States

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Stage III Multiple Myeloma
Stage II Multiple Myeloma
Stage I Multiple Myeloma
Interventions
First Posted Date
2010-01-27
Last Posted Date
2017-12-12
Lead Sponsor
Mayo Clinic
Target Recruit Count
64
Registration Number
NCT01057225
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2010-01-26
Last Posted Date
2017-05-03
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
59
Registration Number
NCT01056276
Locations
🇺🇸

Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States

🇺🇸

Los Robles Hospital and Medical Center, Thousand Oaks, California, United States

🇺🇸

Florida Cancer Specialists, Ft. Myers, Florida, United States

and more 10 locations

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2
Withdrawn
Conditions
Multiple Myeloma
Plasma Cell Myeloma
Interventions
Drug: bortezomib
Drug: cisplatin
Drug: cyclophosphamide
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: lenalidomide
Drug: melphalan
Drug: thalidomide
Genetic: gene expression analysis
Genetic: microarray analysis
Other: laboratory biomarker analysis
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
First Posted Date
2010-01-25
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT01055301
Locations
🇺🇸

Harborview Medical Center, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

Group Health Central Hospital, Seattle, Washington, United States

and more 18 locations

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2010-01-22
Last Posted Date
2021-10-13
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
27
Registration Number
NCT01054144
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1
Completed
Conditions
Refractory Multiple Myeloma
Interventions
First Posted Date
2010-01-15
Last Posted Date
2020-02-11
Lead Sponsor
Mayo Clinic
Target Recruit Count
70
Registration Number
NCT01049945
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 2 locations

The Effect of Dexamethasone on Cortisol Levels in Patients Undergoing Thyroid Surgery

Phase 4
Withdrawn
Conditions
Adrenal Insufficiency
Interventions
Other: Placebo
Drug: Dexamethasone
First Posted Date
2010-01-11
Last Posted Date
2016-04-19
Lead Sponsor
St. Paul's Hospital, Canada
Registration Number
NCT01045876
Locations
🇨🇦

St Paul's Hospital, Vancouver, British Columbia, Canada

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Phase 1
Completed
Conditions
Myeloma
Interventions
Drug: Bendamustine
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Aspirin
Drug: Prophylaxis
Drug: Antibiotic
Other: Biweekly Follow Up
Other: Cyclical Follow Up
Other: Restaging
Other: Post-Treatment Follow Up
First Posted Date
2010-01-05
Last Posted Date
2017-07-31
Lead Sponsor
Robert Redner, MD
Target Recruit Count
29
Registration Number
NCT01042704
Locations
🇺🇸

UPMC Cancer Centers - Arnold Palmer at Mountain View, Greensburg, Pennsylvania, United States

🇺🇸

UPMC Cancer Centers - Arnold Palmer at Oakbrook, Greensburg, Pennsylvania, United States

🇺🇸

Hematology/Oncology - Private Practice, McKeesport, Pennsylvania, United States

and more 19 locations
© Copyright 2025. All Rights Reserved by MedPath